What question did this study set out to answer?

To determine whether intermediate-dose cytarabine is noninferior to high-dose cytarabine in overall survival and evaluates its safety profile as postinduction therapy in newly diagnosed acute myeloid leukemia.

June 24, 2025NEJM Evidence

Intermediate-Dose Cytarabine as Postinduction AML Therapy

View Full Paper

Ask AI

Bookmark

Authors

MHMathilde HunaultCentre National de la Recherche Scientifique CPCécile PautasCentre Hospitalier Universitaire Henri-Mondor SBSarah BertoliMemorial Sloan Kettering Cancer Center

Discussion

Member takes

Implication

Randomized noninferiority trial shows noninferior overall survival with intermediate-dose cytarabine in acute myeloid leukemia, indicating reduced toxicity without loss of efficacy.

Key Points

To determine whether intermediate-dose cytarabine is noninferior to high-dose cytarabine in overall survival and evaluates its safety profile as postinduction therapy in newly diagnosed acute myeloid leukemia.
Randomized controlled trial evaluating intermediate-dose cytarabine (IDAC) versus high-dose cytarabine (HDAC) postinduction therapy in 1,132 patients aged 18 to 60 years with newly diagnosed AML (EudraCT 2014-000699-24, NCT02416388).
Patients with intermediate- and adverse-risk AML were eligible for allogeneic hematopoietic stem cell transplantation (HSCT) in first remission.
The primary endpoint was overall survival (OS) in a per-protocol population, adjusted for European LeukemiaNet 2022 risk group, induction anthracycline use, induction response, and time-dependent HSCT.
Estimated 5-year overall survival was 59.3% (95% CI, 55.0 to 63.3) in the IDAC arm versus 57.5% (95% CI, 53.3 to 61.5) in the HDAC arm (adjusted HR, 0.96; 95% CI, 0.80 to 1.15; P=0.0042 for noninferiority).
Subgroup analyses showed no significant interaction between cytarabine dose and patient characteristics, including ELN 2022 risk category or pre-randomization response to induction.
Patients receiving intermediate-dose cytarabine experienced lower severity of chemotherapy-induced myelosuppression and fewer related adverse events than those receiving high-dose therapy.

Cite This Study

Hunault et al. (2025) studied this question.

synapsesocial.com/papers/6a0eeb72b7cc3b883f22e2a2 https://doi.org/10.1056/evidoa2400326

View Full Paper

Ask AI

Bookmark

Implication

Randomized noninferiority trial shows noninferior overall survival with intermediate-dose cytarabine in acute myeloid leukemia, indicating reduced toxicity without loss of efficacy.

Intermediate-Dose Cytarabine as Postinduction AML Therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Intermediate-Dose Cytarabine as Postinduction AML Therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider